Guy Chouinard

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. doi request reprint Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching
    Howard C Margolese
    Department of Psychiatry, McGill University, Montreal, Quebec, Canada
    Int Clin Psychopharmacol 25:180-2. 2010
  2. ncbi request reprint Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia
    Howard C Margolese
    Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 50:703-14. 2005
  3. ncbi request reprint Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction
    Howard C Margolese
    Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 50:541-7. 2005
  4. ncbi request reprint Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
    Guy Chouinard
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, and Department of Psychiatry, McGill University, Montreal, QC, Canada, H3A 1A1
    Schizophr Res 76:247-65. 2005
  5. ncbi request reprint Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use
    Emmanuelle Levy
    Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 49:398-402. 2004
  6. ncbi request reprint New nomenclature for drug-induced movement disorders including tardive dyskinesia
    Guy Chouinard
    Fernand Seguin Research Center, Louis H Lafontaine Hospital, University of Montreal and the Allan Memorial Institute, McGill University Health Center, Montreal, Quebec, Canada
    J Clin Psychiatry 65:9-15. 2004
  7. ncbi request reprint Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound
    Guy Chouinard
    Centre de Recherche Fernand Seguin, Psychopharmacologie, Departement de Psychiatrie, Universite de Montreal, Hôpital Louis Lafontaine, Montreal, Quebec, Canada
    J Clin Psychiatry 65:7-12. 2004
  8. ncbi request reprint Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena
    Nadeem H Bhanji
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, QC
    Can J Clin Pharmacol 13:e69-74. 2006
  9. ncbi request reprint Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder
    Howard C Margolese
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, Quebec, Canada
    J Clin Psychopharmacol 22:347-52. 2002
  10. ncbi request reprint A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia
    Nadeem H Bhanji
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, QC, Canada
    Eur Neuropsychopharmacol 14:87-92. 2004

Collaborators

  • Paul Sandor
  • Julie Eve Desmarais
  • Howard C Margolese
  • Linda Beauclair
  • Nadeem H Bhanji
  • Lawrence Annable
  • Emmanuel Lévy
  • Theodore T Kolivakis
  • Robert Miller
  • Gerald Pfeffer
  • Emmanuelle Levy
  • Yves Dion
  • Yael Wolf
  • Florian Ferreri
  • Catherine Agbokou
  • Theodore Kolivakis
  • Marie Claire Bélanger

Detail Information

Publications15

  1. doi request reprint Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching
    Howard C Margolese
    Department of Psychiatry, McGill University, Montreal, Quebec, Canada
    Int Clin Psychopharmacol 25:180-2. 2010
    ..Generic switching should be decided on a case-by-case basis with disclosure of potential consequences to the patient...
  2. ncbi request reprint Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia
    Howard C Margolese
    Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 50:703-14. 2005
    ..We sought to explore the incidence and management of TD in the era of atypical antipsychotics because it remains an important iatrogenic adverse effect...
  3. ncbi request reprint Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction
    Howard C Margolese
    Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 50:541-7. 2005
    ..Several mechanisms may exist for this phenomenon. Mechanisms for the lower incidence of TD with atypical antipsychotics also remain to be fully understood. We undertook to explore and better understand these mechanisms...
  4. ncbi request reprint Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
    Guy Chouinard
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, and Department of Psychiatry, McGill University, Montreal, QC, Canada, H3A 1A1
    Schizophr Res 76:247-65. 2005
    ..ESRS specificity was investigated through two different approaches, path analyses and ANCOVA PANSS factors changes, which found that ESRS measurement of drug-induced EPS is valid and discriminative from psychiatric symptoms...
  5. ncbi request reprint Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use
    Emmanuelle Levy
    Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec
    Can J Psychiatry 49:398-402. 2004
    ..This study examines the links among diabetes, tardive dyskinesia (TD), and other extrapyramidal symptoms (EPS) in schizophrenia outpatients treated with typical and atypical antipsychotics...
  6. ncbi request reprint New nomenclature for drug-induced movement disorders including tardive dyskinesia
    Guy Chouinard
    Fernand Seguin Research Center, Louis H Lafontaine Hospital, University of Montreal and the Allan Memorial Institute, McGill University Health Center, Montreal, Quebec, Canada
    J Clin Psychiatry 65:9-15. 2004
    ..This new classification system will provide clinicians and researchers across specialties a more precise language, which will hopefully improve the diagnosis of and research criteria for D-IMD...
  7. ncbi request reprint Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound
    Guy Chouinard
    Centre de Recherche Fernand Seguin, Psychopharmacologie, Departement de Psychiatrie, Universite de Montreal, Hôpital Louis Lafontaine, Montreal, Quebec, Canada
    J Clin Psychiatry 65:7-12. 2004
    ..Although as a class benzodiazepines act rapidly and are well tolerated, their use presents clinical issues such as dependence, rebound anxiety, memory impairment, and discontinuation syndrome...
  8. ncbi request reprint Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena
    Nadeem H Bhanji
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, QC
    Can J Clin Pharmacol 13:e69-74. 2006
    ..To describe tardive rebound anxiety phenomena (panic, anxiety and insomnia) following abrupt paroxetine discontinuation...
  9. ncbi request reprint Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder
    Howard C Margolese
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, Quebec, Canada
    J Clin Psychopharmacol 22:347-52. 2002
    ..Seeman and Tallerico3 have proposed pharmacologic explanations for quetiapine and clozapine drug-induced rebound phenomena...
  10. ncbi request reprint A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia
    Nadeem H Bhanji
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, Montreal, QC, Canada
    Eur Neuropsychopharmacol 14:87-92. 2004
    ..Besides positive and negative symptom control, they may improve cognition. Due to their limited availability as oral agents only, benefits are limited by noncompliance...
  11. pmc The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs
    Guy Chouinard
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, McGill University, Montreal, Que, Canada
    J Psychiatry Neurosci 31:168-76. 2006
    ....
  12. ncbi request reprint Topiramate-induced weight loss in schizophrenia: a retrospective case series study
    Emmanuel Lévy
    Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec, Canada
    Can J Clin Pharmacol 14:e234-9. 2007
    ..Atypical antipsychotics have been associated with weight gain. This study examines the efficacy of adjunctive topiramate in patients with schizophrenia and schizoaffective disorder with antipsychotic-induced weight gain...
  13. ncbi request reprint Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia
    Gerald Pfeffer
    Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    Int Clin Psychopharmacol 20:179-81. 2005
    ..Gabapentin may be effective by mechanisms similar to its action in restless legs syndrome and Parkinsonism, and/or via the GABA neurotransmitter system...
  14. pmc Interrelations between psychiatric symptoms and drug-induced movement disorder
    Guy Chouinard
    Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, McGill University, Montreal, Que, Canada
    J Psychiatry Neurosci 31:177-80. 2006
    ....
  15. ncbi request reprint Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial
    Yves Dion
    Allan Memorial Institute, Royal Victoria Hospital and Department of Psychiatry, McGill University, Montreal, Quebec, Canada
    J Clin Psychopharmacol 22:31-9. 2002
    ..Risperidone did not increase obsessive-compulsive symptoms. Fatigue and somnolence were the most common adverse events associated with risperidone...